CN Patent

CN120641090A — 向哺乳期女性施用索安非托的方法

Assigned to Axum Malta Ltd · Expires 2025-09-12 · 1y expired

What this patent protects

根据一些实施方案，本文中提供了用于降低从用索安非托治疗的受试者获得的母乳喂养的婴儿的由索安非托引起的不良事件的可能性的方法，包括：以约37.5mg至约300mg的每日剂量向受试者口服施用索安非托；和向婴儿喂养在向受试者施用索安非托之后至少约5小时的来自受试者的母乳，从而降低婴儿的索安非托不良事件的可能性。

USPTO Abstract

根据一些实施方案，本文中提供了用于降低从用索安非托治疗的受试者获得的母乳喂养的婴儿的由索安非托引起的不良事件的可能性的方法，包括：以约37.5mg至约300mg的每日剂量向受试者口服施用索安非托；和向婴儿喂养在向受试者施用索安非托之后至少约5小时的来自受试者的母乳，从而降低婴儿的索安非托不良事件的可能性。

Drugs covered by this patent

solriamfetol-hydrochloride (SOLRIAMFETOL HYDROCHLORIDE)

Patent Metadata

Patent number: CN120641090A
Jurisdiction: CN
Classification: —
Expires: 2025-09-12
Drug substance claim: No
Drug product claim: No
Assignee: Axum Malta Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.